Daiwa Securities Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Daiwa Securities Group’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14	Closed	-$1K	–	1261
2020 Q3	$1K	Hold	14	–	–	﹤0.01%	1160
2020 Q2	$2K	Hold	14	–	–	﹤0.01%	1157
2020 Q1	$2K	Hold	14	–	–	﹤0.01%	1156
2019 Q4	$2K	Hold	14	–	–	﹤0.01%	1158
2019 Q3	$2K	Hold	14	–	–	﹤0.01%	1124
2019 Q2	$3K	Buy	14 +4	+40%	+$856	﹤0.01%	1126
2019 Q1	$2K	Hold	10	–	–	﹤0.01%	1127
2018 Q4	$2K	Hold	10	–	–	﹤0.01%	1103
2018 Q3	$2K	Hold	10	–	–	﹤0.01%	1125
2018 Q2	$2K	Hold	10	–	–	﹤0.01%	1135
2018 Q1	$2K	Buy	+10	New	+$2.25K	﹤0.01%	1123

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Daiwa Securities Group's CRBP Position: Q4 2020 in Review

Daiwa Securities Group sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 14 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in CRBP in Q1 2018 and held it in 11 quarters. The position peaked at $3K in Q2 2019. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

Daiwa Securities Group reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Daiwa Securities Group sold 14 Corbus Pharmaceuticals shares in Q4 2020, an estimated $1K.
Daiwa Securities Group first reported a position in Corbus Pharmaceuticals in Q1 2018 and held it in 11 quarters.
Daiwa Securities Group's Corbus Pharmaceuticals position peaked at $3K in Q2 2019.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Daiwa Securities Group's 13F filing for Q4 2020, filed 4 Feb 2021.